Asia's first man! Wang Yongjun, president of Tiantan Hospital, won the world's highest achievement award in the field of stroke

On October 27, at the 14th World Stroke Conference, Wang Yongjun, president of Beijing Tiantan Hospital affiliated to Capital Medical University, won the "Chairman's Award", the highest achievement award of the World Stroke Organization (WSO), becoming the first Asian
country to receive this award.
In recent years, China's research in the field of cerebrovascular diseases has made frequent achievements, and has become an important force
influencing the research of cerebrovascular diseases in the world.
The conference also set up the "China Forum" for the first time, and more "Chinese scholars" and "China solutions" appeared on
the world stage.

The World Stroke Organization's President's Award recognizes international leaders who have made significant contributions to stroke diagnosis and research, and only one recipient
is selected each year among stroke researchers worldwide.
"As a neurologist, Professor Wang Yongjun has been committed to the clinical and scientific research of cerebrovascular diseases for 40 years
.
He and his team created the 'CHANCE' program of short-term combined antiplatelet therapy for non-disabling ischemic cerebrovascular disease, ushering in the era of ischemic cerebrovascular disease combined with antiplatelet therapy; he pioneered the 'CHANCE-2' trial, a combination antiplatelet therapy study guided by rapid drug genetic testing, which made outstanding contributions to the precise clinical diagnosis and treatment and research of stroke.
He initiated the Chinese National Stroke Registry (CNSR), used multi-omics and biomarker studies to discover the role of inflammatory mechanisms in stroke recurrence, and initiated the 'CHANCE-3' trial on colchicine for the secondary prevention
of ischemic cerebrovascular disease.
Mark Fisher, president of the World Stroke Organization, said in his award speech that Wang Yongjun and his team have made many outstanding contributions
in reducing the risk of residual recurrence of ischemic cerebrovascular disease.

"I want to tell a story
called 'CHANCE.
' For more than 10 years, my colleagues and I have been engaged in a work that is to reduce the risk of recurrence of ischemic cerebrovascular disease and give patients more and better 'opportunities'
to live a better life.
At the branch venue of Beijing Tiantan Hospital, Wang Yongjun shared his research process
with colleagues from all over the world.

Acute ischemic cerebrovascular disease, commonly known as "cerebral infarction", is divided into two categories
: disabling and non-disabled.
For non-disabling "cerebral infarction", reducing recurrence is the goal
that researchers in various countries have always pursued.
At the end of the 90s, after decades of exploration, scientists obtained solid evidence-based medical evidence that early aspirin use could reduce the risk of
disabling "cerebral infarction" and recurrence in this part of patients.
The scientists are not stopping there, but hope to find an antiplatelet drug that is not related to the aspirin mechanism of action, and by combining the two drugs, further reduce the risk of
stroke recurrence.
But in three subsequent large-scale international experiments, scientists found that the combination of the two drugs significantly increased the risk of
cerebral hemorrhage in patients.

"The theory is feasible, and we believe that the key is to find the 'sweet spot'
where the two drugs are used, the applicable patient and the cycle of use.
" Wang Yongjun said
.
Based on this, a study entitled "Efficacy study of clopidogrel in people at high risk of acute non-disabling cerebrovascular disease events" was officially launched
.

The abbreviation of the name of this complex project is precisely the English "opportunity" - "CHANCE"
.

From October 2009 to July 2012, the research team screened a total of 5170 patients
with high-risk non-disabling cerebrovascular disease from 114 domestic clinical trial sites.
Through the mode of "double-blind double simulation parallel control", this key "sweet spot" was finally found - "light stroke", "within 24 hours of onset" and "aspirin + clopidogrel combined for 21 days"
.
After a number of international large-scale experiments, this scheme is suitable for all kinds of people
.
The results of the "CHANCE" study, released in 2013, shocked the world, and now the Chinese solution has become the "gold standard"
of stroke treatment worldwide.

Wang and his team did not stop, in response to the problem that clopidogrel is not effective in some people, they further explored and found that certain gene mutations were responsible for this result, especially a gene
called "CYP2C19".
58.
8% of the Chinese group has this gene function loss, much higher than European and American countries, which is even worse for Chinese stroke patients
.
The research team "shot" again and found a drug ticagrelor with similar efficacy to clopidogrel but not metabolized by "CYP2C19", which solved this problem
.
This is the "CHANCE-2" study
.
During this study, in order to solve the problem of rapid genetic screening, the research team also "piggybacked" to develop a rapid genetic testing method, which can shorten the genetic testing time from the traditional blood drawing of several hours to more than a dozen hours, to 85 minutes
.

Before the "CHANCE" study, the risk of recurrence of non-disabling ischemic cerebrovascular disease was 11%, and the "CHANCE" program reduced this figure to 8.
2%, and further to 6%
after "CHANCE-2".
"For every patient, as long as there is a relapse, it is 100
percent.
" Wang Yongjun said that making the risk of recurrence lower and lower is the goal that the team has always pursued, and now that the "CHANCE-3" study has been launched, 300 hospitals have participated
.

"That's the story of
'CHANCE'.
This story belongs not only to me, but to my team, researchers around the world, and all the patients
involved in the study.
At the end of his speech, Wang Yongjun set aside a special time to express his sincere gratitude
.

From one person to a group of people
.
Since the beginning of this year, domestic researchers have published 5 heavyweight articles in top international medical journals, which has also set a new record for the publication of top journal articles in this field of the year - more and more Chinese scientists are pursuing more "opportunities" for stroke patients around the world to "
live well".

At the World Stroke Congress, for the first time, a forum was held specifically for Chinese scholars - the "CSA & WSO Joint Forum" jointly organized by the Chinese Stroke Society and the World Stroke Organization, where scholars from China will present the latest research results and research progress
.

"The 'CHANCE' study has opened the door
for cerebrovascular disease research in China.
In recent years, more and more Chinese scholars have emerged on the world stage of cerebrovascular disease research, and hope that more Chinese researchers will join the team of cerebrovascular disease research in the future, strengthen exchanges with counterparts in other countries, and work together
to promote human brain health.
Mark Fisher said
.